Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Genetic Aberration Analysis in Thai Colorectal Adenoma and Early-Stage Adenocarcinoma Patients by Whole-Exome Sequencing.

Intarajak T, Udomchaiprasertkul W, Bunyoo C, Yimnoon J, Soonklang K, Wiriyaukaradecha K, Lamlertthon W, Sricharunrat T, Chaiwiriyawong W, Siriphongpreeda B, Sutheeworapong S, Kusonmano K, Kittichotirat W, Thammarongtham C, Jenjaroenpun P, Wongsurawat T, Nookaew I, Auewarakul C, Cheevadhanarak S.

Cancers (Basel). 2019 Jul 12;11(7). pii: E977. doi: 10.3390/cancers11070977.

2.

PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma.

Holst F, Werner HMJ, Mjøs S, Hoivik EA, Kusonmano K, Wik E, Berg A, Birkeland E, Gibson WJ, Halle MK, Trovik J, Cherniack AD, Kalland KH, Mills GB, Singer CF, Krakstad C, Beroukhim R, Salvesen HB.

Clin Cancer Res. 2019 Jan 1;25(1):334-345. doi: 10.1158/1078-0432.CCR-18-0452. Epub 2018 Nov 15.

3.

Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer.

Kusonmano K, Halle MK, Wik E, Hoivik EA, Krakstad C, Mauland KK, Tangen IL, Berg A, Werner HMJ, Trovik J, Øyan AM, Kalland KH, Jonassen I, Salvesen HB, Petersen K.

PLoS One. 2018 Nov 1;13(11):e0206665. doi: 10.1371/journal.pone.0206665. eCollection 2018.

4.

HER2 expression patterns in paired primary and metastatic endometrial cancer lesions.

Halle MK, Tangen IL, Berg HF, Hoivik EA, Mauland KK, Kusonmano K, Berg A, Hurtado A, Kalland KH, Øyan AM, Stefansson I, Vintermyr OK, Werner HM, Haldorsen IS, Trovik J, Salvesen HB, Krakstad C.

Br J Cancer. 2018 Feb 6;118(3):378-387. doi: 10.1038/bjc.2017.422. Epub 2017 Nov 23.

5.

PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer.

Mjos S, Werner HMJ, Birkeland E, Holst F, Berg A, Halle MK, Tangen IL, Kusonmano K, Mauland KK, Oyan AM, Kalland KH, Lewis AE, Mills GB, Krakstad C, Trovik J, Salvesen HB, Hoivik EA.

Sci Rep. 2017 Aug 31;7(1):10240. doi: 10.1038/s41598-017-10717-z.

6.

Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study.

Halle MK, Ojesina AI, Engerud H, Woie K, Tangen IL, Holst F, Høivik E, Kusonmano K, Haldorsen IS, Vintermyr OK, Trovik J, Bertelsen BI, Salvesen HB, Krakstad C.

Am J Obstet Gynecol. 2017 Oct;217(4):432.e1-432.e17. doi: 10.1016/j.ajog.2017.05.068. Epub 2017 Jun 24.

PMID:
28599900
7.

Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival.

Mauland KK, Wik E, Hoivik EA, Kusonmano K, Halle MK, Berg A, Haugland HK, Øyan AM, Kalland KH, Stefansson IM, Akslen LA, Krakstad C, Trovik J, Werner HM, Salvesen HB.

Oncotarget. 2017 Feb 7;8(6):9696-9707. doi: 10.18632/oncotarget.14201.

8.

Gene Expression Analysis Through Network Biology: Bioinformatics Approaches.

Kusonmano K.

Adv Biochem Eng Biotechnol. 2017;160:15-32. doi: 10.1007/10_2016_44. Review.

PMID:
27830311
9.

Informatics for Metabolomics.

Kusonmano K, Vongsangnak W, Chumnanpuen P.

Adv Exp Med Biol. 2016;939:91-115.

PMID:
27807745
10.

The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis.

Gibson WJ, Hoivik EA, Halle MK, Taylor-Weiner A, Cherniack AD, Berg A, Holst F, Zack TI, Werner HM, Staby KM, Rosenberg M, Stefansson IM, Kusonmano K, Chevalier A, Mauland KK, Trovik J, Krakstad C, Giannakis M, Hodis E, Woie K, Bjorge L, Vintermyr OK, Wala JA, Lawrence MS, Getz G, Carter SL, Beroukhim R, Salvesen HB.

Nat Genet. 2016 Aug;48(8):848-55. doi: 10.1038/ng.3602. Epub 2016 Jun 27.

11.

ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma.

Krakstad C, Tangen IL, Hoivik EA, Halle MK, Berg A, Werner HM, Ræder MB, Kusonmano K, Zou JX, Øyan AM, Stefansson I, Trovik J, Kalland KH, Chen HW, Salvesen HB.

Oncotarget. 2015 Sep 29;6(29):28440-52. doi: 10.18632/oncotarget.4955.

12.

Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer.

Stefansson IM, Raeder M, Wik E, Mannelqvist M, Kusonmano K, Knutsvik G, Haldorsen I, Trovik J, Øyan AM, Kalland KH, Staff AC, Salvesen HB, Akslen LA.

Oncotarget. 2015 Apr 30;6(12):10634-45.

13.

Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.

Berg A, Hoivik EA, Mjøs S, Holst F, Werner HM, Tangen IL, Taylor-Weiner A, Gibson WJ, Kusonmano K, Wik E, Trovik J, Halle MK, Øyan AM, Kalland KH, Cherniack AD, Beroukhim R, Stefansson I, Mills GB, Krakstad C, Salvesen HB.

Oncotarget. 2015 Jan 20;6(2):1327-39.

14.

Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions.

Tangen IL, Werner HM, Berg A, Halle MK, Kusonmano K, Trovik J, Hoivik EA, Mills GB, Krakstad C, Salvesen HB.

Eur J Cancer. 2014 Nov;50(17):3003-10. doi: 10.1016/j.ejca.2014.09.003. Epub 2014 Sep 30.

PMID:
25281525
15.

Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations.

Wik E, Trovik J, Kusonmano K, Birkeland E, Raeder MB, Pashtan I, Hoivik EA, Krakstad C, Werner HM, Holst F, Mjøs S, Halle MK, Mannelqvist M, Mauland KK, Oyan AM, Stefansson IM, Petersen K, Simon R, Cherniack AD, Meyerson M, Kalland KH, Akslen LA, Salvesen HB.

Gynecol Oncol. 2014 Sep;134(3):599-606. doi: 10.1016/j.ygyno.2014.06.026. Epub 2014 Jul 1.

PMID:
24995579
16.

Dip in the gene pool: metagenomic survey of natural coccolithovirus communities.

Pagarete A, Kusonmano K, Petersen K, Kimmance SA, Martínez Martínez J, Wilson WH, Hehemann JH, Allen MJ, Sandaa RA.

Virology. 2014 Oct;466-467:129-37. doi: 10.1016/j.virol.2014.05.020. Epub 2014 Jun 16.

17.

High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors.

Engerud H, Tangen IL, Berg A, Kusonmano K, Halle MK, Oyan AM, Kalland KH, Stefansson I, Trovik J, Salvesen HB, Krakstad C.

Br J Cancer. 2014 Jul 8;111(1):78-84. doi: 10.1038/bjc.2014.262. Epub 2014 May 22.

18.

Switch in FOXA1 status associates with endometrial cancer progression.

Tangen IL, Krakstad C, Halle MK, Werner HM, Oyan AM, Kusonmano K, Petersen K, Kalland KH, Akslen LA, Trovik J, Hurtado A, Salvesen HB.

PLoS One. 2014 May 21;9(5):e98069. doi: 10.1371/journal.pone.0098069. eCollection 2014.

19.

Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.

Hoivik EA, Kusonmano K, Halle MK, Berg A, Wik E, Werner HM, Petersen K, Oyan AM, Kalland KH, Krakstad C, Trovik J, Widschwendter M, Salvesen HB.

Oncotarget. 2014 Feb 28;5(4):1052-61.

20.

High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition.

Wik E, Birkeland E, Trovik J, Werner HM, Hoivik EA, Mjos S, Krakstad C, Kusonmano K, Mauland K, Stefansson IM, Holst F, Petersen K, Oyan AM, Simon R, Kalland KH, Ricketts W, Akslen LA, Salvesen HB.

Clin Cancer Res. 2013 May 1;19(9):2331-41. doi: 10.1158/1078-0432.CCR-12-3413. Epub 2013 Mar 28.

21.

High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated.

Krakstad C, Birkeland E, Seidel D, Kusonmano K, Petersen K, Mjøs S, Hoivik EA, Wik E, Halle MK, Øyan AM, Kalland KH, Werner HM, Trovik J, Salvesen H.

PLoS One. 2012;7(12):e52795. doi: 10.1371/journal.pone.0052795. Epub 2012 Dec 27.

22.

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.

Birkeland E, Wik E, Mjøs S, Hoivik EA, Trovik J, Werner HM, Kusonmano K, Petersen K, Raeder MB, Holst F, Øyan AM, Kalland KH, Akslen LA, Simon R, Krakstad C, Salvesen HB.

Br J Cancer. 2012 Dec 4;107(12):1997-2004. doi: 10.1038/bjc.2012.477. Epub 2012 Oct 25.

23.

ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas.

Werner HM, Berg A, Wik E, Birkeland E, Krakstad C, Kusonmano K, Petersen K, Kalland KH, Oyan AM, Akslen LA, Trovik J, Salvesen HB.

Mod Pathol. 2013 Mar;26(3):428-34. doi: 10.1038/modpathol.2012.174. Epub 2012 Oct 19.

24.

Anti-cancer drug development: computational strategies to identify and target proteins involved in cancer metabolism.

Mak L, Liggi S, Tan L, Kusonmano K, Rollinger JM, Koutsoukas A, Glen RC, Kirchmair J.

Curr Pharm Des. 2013;19(4):532-77. Review.

PMID:
23016852
25.

Draft genome sequence of Arthrospira platensis C1 (PCC9438).

Cheevadhanarak S, Paithoonrangsarid K, Prommeenate P, Kaewngam W, Musigkain A, Tragoonrung S, Tabata S, Kaneko T, Chaijaruwanich J, Sangsrakru D, Tangphatsornruang S, Chanprasert J, Tongsima S, Kusonmano K, Jeamton W, Dulsawat S, Klanchui A, Vorapreeda T, Chumchua V, Khannapho C, Thammarongtham C, Plengvidhya V, Subudhi S, Hongsthong A, Ruengjitchatchawalya M, Meechai A, Senachak J, Tanticharoen M.

Stand Genomic Sci. 2012 Mar 19;6(1):43-53. doi: 10.4056/sigs.2525955. Epub 2012 Mar 5.

26.

Effects of pooling samples on the performance of classification algorithms: a comparative study.

Kusonmano K, Netzer M, Baumgartner C, Dehmer M, Liedl KR, Graber A.

ScientificWorldJournal. 2012;2012:278352. doi: 10.1100/2012/278352. Epub 2012 Apr 30.

27.

Lipocalin 2 expression is associated with aggressive features of endometrial cancer.

Mannelqvist M, Stefansson IM, Wik E, Kusonmano K, Raeder MB, Øyan AM, Kalland KH, Moses MA, Salvesen HB, Akslen LA.

BMC Cancer. 2012 May 6;12:169. doi: 10.1186/1471-2407-12-169.

28.

MethyCancer: the database of human DNA methylation and cancer.

He X, Chang S, Zhang J, Zhao Q, Xiang H, Kusonmano K, Yang L, Sun ZS, Yang H, Wang J.

Nucleic Acids Res. 2008 Jan;36(Database issue):D836-41. Epub 2007 Sep 21.

Supplemental Content

Loading ...
Support Center